Nintedanib ‘Superior’ to Bevacizumab for Mesothelioma TreatmentTreatment & Doctors
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
Povtak, T. (2022, January 12). Nintedanib ‘Superior’ to Bevacizumab for Mesothelioma Treatment. Asbestos.com. Retrieved February 6, 2023, from https://www.asbestos.com/news/2018/06/11/nintedanib-closer-approval-mesothelioma/
Povtak, Tim. "Nintedanib ‘Superior’ to Bevacizumab for Mesothelioma Treatment." Asbestos.com, 12 Jan 2022, https://www.asbestos.com/news/2018/06/11/nintedanib-closer-approval-mesothelioma/.
Povtak, Tim. "Nintedanib ‘Superior’ to Bevacizumab for Mesothelioma Treatment." Asbestos.com. Last modified January 12, 2022. https://www.asbestos.com/news/2018/06/11/nintedanib-closer-approval-mesothelioma/.
Researchers in Austria, Germany and Hungary have added to the growing belief that the anti-cancer drug nintedanib may soon become a significant part of standard-of-care treatment for malignant pleural mesothelioma.
In their study published recently in Clinical Cancer Research, nintedanib demonstrated an ability to inhibit the growth and the migration of mesothelioma tumor cells effectively in animal models.
“This is a step in the right direction, another part of the evolutionary process of treatment advancements with this difficult disease,” Dr. Balazs Hegedus, department of thoracic surgery, University of Duisburg-Essen, told Asbestos.com. “This is an important finding.”
Nintedanib, also known by brand names Ofev and Vargetef, works by targeting a specific molecule expressed by most mesothelioma tumor cells. It functions much like bevacizumab (Avastin), one of the world’s best-selling cancer drugs, but it does so more effectively, according to this latest study.
“Importantly, this anti-tumor effect of nintedanib in experimental animals was stronger than that of bevacizumab,” Dr. Balazs Dome, head of the Translational Thoracic Oncology Program at the Medical University of Vienna in Austria said. “A key message is that nintedanib be considered superior as part of systemic anti-tumor therapy.”
Nintedanib Smothers Tumor Cells
Nintedanib inhibits tumor growth by denying cancer cells the oxygen and nutrients they need.
The drug is already approved for use with pulmonary fibrosis and certain cases of lung cancer.
There is a multicenter clinical trial, crossing several countries, already testing its effectiveness in combination with chemotherapy. It is called the LUME-Meso trial and is being watched closely.
Clinical trial sites participating within the United States include:
University of Texas MD Anderson Cancer Center, Houston
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Greenville Health System, Greenville, S.C.
Comprehensive Cancer Centers of Nevada, Henderson
Nintedanib Gaining Momentum
The Barbara Ann Karmanos Cancer Institute in Detroit is hosting the only U.S. trial involving stand-alone treatment with nintedanib as second-line therapy for pleural mesothelioma.
The Institut Gustave Roussy in France is running a clinical trial for mesothelioma that involves nintedanib in combination with pembrolizumab (Keytruda).
The U.S. Food and Drug Administration granted nintedanib orphan drug designation in December of 2016, giving it limited availability while moving through the approval process.
“It will be exciting to see the outcome of the clinical trials,” Hegendus said. “We already know it is a safe drug and the inhibitory effect is real.”
Early LUME-Meso Results Are Impressive
Early results from the trial have been promising. They include a 9.4-month progression-free survival, which was almost double compared to chemotherapy alone.
The median overall survival benefit was 18.3 months, compared to 14.2 months for just chemotherapy.
Standard-of-care treatment for unresectable mesothelioma has been relatively ineffective for many years with a one-year survival rate hovering around 50 percent.
The regulatory industry in the United Kingdom granted early access designation earlier this year to nintedanib for use with pleural mesothelioma.
Doctors in the U.K. have been using it in combination with chemotherapy for certain lung cancers.